This study is currently not recruiting participants.

PORTICO: A randomized double-blind placebo-controlled prospective multicenter parallel group study to assess the safety and efficacy of macitentan in patients with portopulmonary hypertension

Investigating an investigational medication for portopulmonary hypertension

Not Recruiting
18 years - 100 years
All
Phase N/A

Brief description of study.

This is a 24 week study to evaluate efficacy and safety of macitentan for treatment of portopulmonary hypertension.

Detailed description of study

This is a 24 week study to evaluate efficacy and safety of macitentan for treatment of portopulmonary hypertension.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: portopulmonary hypertension
  • Age: 18 years - 100 years
  • Gender: All

This study investigates the effects of an investigational medication on portopulmonary hypertension, a condition where high blood pressure occurs in the lungs due to liver disease. The purpose is to evaluate how well the medication works and how safe it is for patients with this condition.

Participants in the study will receive either the investigational medication or a placebo. A placebo is an inactive substance that looks like the investigational medication but does not contain any medicine. The study will monitor the participants' health and response to the treatment.

  • Who can participate: Age criteria and key eligibility factors are not provided.
  • Study details: Participants will be randomly assigned to receive either the investigational medication or a placebo. A placebo is an inactive substance that looks like the investigational medication but does not contain any medicine.
  • Study Timelines: The study will last 24 weeks.
Updated on 19 Feb 2024. Study ID: 1503046583

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Connect with the study team